open access

Ahead of Print
Original article
Submitted: 2023-08-08
Accepted: 2023-09-11
Published online: 2023-10-31
Get Citation

AEBP1 exacerbates myocardial ischemia-reperfusion injury via inhibition of IκBα

Wei-Na Xue1
·
Pubmed: 37957937
Affiliations
  1. Cath Lab, Zhangjiakou First Hospital, Zhangjiakou, Hebei Province, P.R. China

open access

Ahead of Print
ORIGINAL ARTICLES
Submitted: 2023-08-08
Accepted: 2023-09-11
Published online: 2023-10-31

Abstract

Myocardial ischemia/reperfusion injury (MIRI) remains a main reason for death after cardiovascular diseases. Up-regulation of adipocyte enhancer binding protein 1 (AEBP1) has been found in ischemic cardiomyopathy patients. However, its influence and detailed mechanisms in MIRI are obscure. In this study, expression of target molecules was determined by RT-qPCR and Western blotting. Cell viability and apoptosis were evaluated by CCK-8 and TUNEL. Inflammatory cytokine levels were assessed by ELISA. Myocardial function and pathological changes were examined by echocardiography and HE staining. Cardiac infarct size was determined by TTC staining. Our data indicated that oxygen-glucose deprivation/reoxygenation (OGD/R) resulted in high expression of AEBP1, while low expression of IκBα in cardiomyocytes. In vitro data indicated that AEBP1 knockdown increased viability, inhibited apoptosis, and inflammation in H9c2 cells under OGD/R. AEBP1 interacted with IκBα to cause IκBα degradation, and facilitated the nuclear translocation of NF-κB. Moreover, IκBα silencing attenuated siAEBP1-medaited inhibition in inflammation and apoptosis of OGD/R-treated H9c2 cells, suggesting that IκBα was involved in the pro-inflammatory action of AEBP1. Finally, deficiency of AEBP1 mitigated MIRI in rats through IκBα/NF-κB pathway. Taken together, AEBP1 exacerbated MIRI through repressing IκBα expression to trigger NF-κB-mediated inflammation.

Abstract

Myocardial ischemia/reperfusion injury (MIRI) remains a main reason for death after cardiovascular diseases. Up-regulation of adipocyte enhancer binding protein 1 (AEBP1) has been found in ischemic cardiomyopathy patients. However, its influence and detailed mechanisms in MIRI are obscure. In this study, expression of target molecules was determined by RT-qPCR and Western blotting. Cell viability and apoptosis were evaluated by CCK-8 and TUNEL. Inflammatory cytokine levels were assessed by ELISA. Myocardial function and pathological changes were examined by echocardiography and HE staining. Cardiac infarct size was determined by TTC staining. Our data indicated that oxygen-glucose deprivation/reoxygenation (OGD/R) resulted in high expression of AEBP1, while low expression of IκBα in cardiomyocytes. In vitro data indicated that AEBP1 knockdown increased viability, inhibited apoptosis, and inflammation in H9c2 cells under OGD/R. AEBP1 interacted with IκBα to cause IκBα degradation, and facilitated the nuclear translocation of NF-κB. Moreover, IκBα silencing attenuated siAEBP1-medaited inhibition in inflammation and apoptosis of OGD/R-treated H9c2 cells, suggesting that IκBα was involved in the pro-inflammatory action of AEBP1. Finally, deficiency of AEBP1 mitigated MIRI in rats through IκBα/NF-κB pathway. Taken together, AEBP1 exacerbated MIRI through repressing IκBα expression to trigger NF-κB-mediated inflammation.

Get Citation

Keywords

myocardial ischemia-reperfusion injury, AEBP1, IκBα, NF-κB, inflammation, apoptosis

About this article
Title

AEBP1 exacerbates myocardial ischemia-reperfusion injury via inhibition of IκBα

Journal

Folia Morphologica

Issue

Ahead of Print

Article type

Original article

Published online

2023-10-31

Page views

249

Article views/downloads

209

DOI

10.5603/fm.96874

Pubmed

37957937

Keywords

myocardial ischemia-reperfusion injury
AEBP1
IκBα
NF-κB
inflammation
apoptosis

Authors

Wei-Na Xue

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, Świętokrzyska 73, 80–180 Gdańsk, Poland

tel.: +48 58 320 94 94, faks: +48 58 320 94 60, e-mail: viamedica@viamedica.pl